Selection of quinolone resistance in Streptococcus pneumoniae exposed in vitro to subinhibitory drug concentrations

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 965-972

  Avrain, Laetitia ^a   Garvey, Mark ^b   Mesaros, Narcisa ^a   Glupczynski, Youri ^c   Mingeot Leclercq, Marie Paule ^a   Piddock, Laura J V ^b   Tulkensp, Paul M ^a   Vanhoof, Raymond ^d   Van bambeke, Françoise ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^d PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

MIC; PatA PatB; PmrA; Reserpine

Indexed keywords

BACTERIAL PROTEIN; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; GARENOXACIN; GEMIFLOXACIN; GENOMIC DNA; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARC; PROTEIN PARE; PROTEIN PROTEIN PATA; PROTEIN PROTEIN PATB; PROTEIN PROTEIN PMRA; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RESERPINE; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE MUTATION; GENE OVEREXPRESSION; GENE SEQUENCE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; GENE EXPRESSION REGULATION, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MUTATION; QUINOLONES; RESERPINE; SELECTION (GENETICS); STREPTOCOCCUS PNEUMONIAE; TIME FACTORS;

EID: 35448979219     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm292     Document Type: Article

References (46)

1. Segreti J, House HR, Siegel RE. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting. Am J Med 2005; 118 Suppl 7A: 21-8S.
2. Chen DK, McGeer A, de Azavedo JC et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341 233-9.
3. Empey PE, Jennings HR, Thornton AC et al. Levofloxacin failure in a patient with pneumococcal pneumonia. Ann Pharmacother 2001; 35: 687-90.
4. Endimiani A, Brigante G, Bettaccini AA et al. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia. BMC Infect Dis 2005; 5: 106.
5. Pletz MW, McGee L, Burkhardt O et al. Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 58-60.
6. Low DE. Quinolone resistance among pneumococci: Therapeutic and diagnostic implications. Clin Infect Dis 2004; 38 Suppl 4: S357-62.
7. Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J Suppl 2002; 36: 3-8s.
8. Ferrara AM. New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance. Infection 2005; 33: 106-14.
9. Pan XS, Ambler J, Mehtar S et al. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996; 40: 2321-6.
10. Janoir C, Zeller V, Kitzis MD et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996; 40: 2760-4.
11. Piddock LJ, Jin YF, Everett MJ. Non-gyrA-mediated ciprofloxacin resistance in laboratory mutants of Streptococcus pneumoniae. J Antimicrob Chemother 1997; 39: 609-15.
12. Baranova NN, Neyfakh AA. Apparent involvement of a multidrug transporter in the fluoroquinolone resistance of Streptococcus pneumoniae. Antimicrob Agents Chemother 1997; 41: 1396-8.
13. Bast DJ, Low DE, Duncan CL et al. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance. Antimicrob Agents Chemother 2000; 44: 3049-54.
14. Brenwald NP, Gill MJ, Wise R. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998; 42: 2032-5.
15. Gill MJ, Brenwald NP, Wise R. Identification of an efflux pump gene, pmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 187-9.
16. Adam HJ, Schurek KN, Nichol KA et al. Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005. Antimicrob Agents Chemother 2007; 51: 198-207.
17. Martinez-Garriga B, Vinuesa T, Hernandez-Borrell J et al. The contribution of efflux pumps to quinolone resistance in Streptococcus pneumoniae clinical isolates. Int J Med Microbiol 2007; 297 187-95.
18. Van Bambeke F, Glupczynski Y, Plesiat P et al. Antibiotic efflux pumps in prokaryotic cells: Occurrence, impact on resistance and strategies for the future of antimicrobial therapy. J Antimicrob Chemother 2003; 51: 1055-65.
19. Marrer E, Schad K, Satoh AT et al. Involvement of the putative ATP-dependent efflux proteins PatA and PatB in fluoroquinolone resistance of a multidrug-resistant mutant of Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50: 685-93.
20. Davies TA, Pankuch GA, Dewasse BE et al. In vitro development of resistance to five quinolones and amoxicillin-clavulanate in Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 1177-82.
21. Van Bambeke F, Michot JM, Van Eldere J et al. Quinolones in 2005: an update. Clin Microbiol Infect 2005; 11: 256-80.
22. Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother 2001; 48 Suppl 1: 5-16.
23. Jumbe NL, Louie A, Miller MH et al. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006; 50: 310-7.
24. Zhanel GG, Walkty A, Nichol K et al. Molecular characterization of fluoroquinolone resistant Streptococcus pneumoniae clinical isolates obtained from across Canada. Diagn Microbiol Infect Dis 2003; 45: 63-7.
25. Pestova E, Millichap JJ, Siddiqui F et al. Non-PmrA-mediated multidrug resistance in Streptococcus pneumoniae. J Antimicrob Chemother 2002; 49: 553-6.
26. Brenwald NP, Appelbaum P, Davies T et al. Evidence for efflux pumps, other than PmrA, associated with fluoroquinolone resistance in Streptococcus pneumoniae. Clin Microbiol Infect 2003; 9: 140-3.
27. Nagai K, Davies TA, Dewasse BE et al. Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae. J Antimicrob Chemother 2001; 48: 385-74.
28. Marrer E, Satoh AT, Johnson MM et al. Global transcriptome analysis of the responses of a fluoroquinolone-resistant Streptococcus pneumoniae mutant and its parent to ciprofloxacin. Antimicrob Agents Chemother 2006; 50: 269-78.
29. Piddock LJ, Johnson MM. Accumulation of 10 fluoroquinolones by wild-type or efflux mutant Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 813-20.
30. McEllistrem MC, Stout JE, Harrison LH. Simplified protocol for pulsed-field gel electrophoresis analysis of Streptococcus pneumoniae. J Clin Microbiol 2000; 38: 351-3.
31. Eaves DJ, Ricci V, Piddock LJ. Expression of acrB, acrF acrD, marA, and soxS in Salmonella enterica serovar Typhimurium: Role in multiple antibiotic resistance. Antimicrob Agents Chemother 2004; 48: 1145-50.
32. Whatmore AM, King SJ, Doherty NC et al. Molecular characterization of equine isolates of Streptococcus pneumoniae: Natural disruption of genes encoding the virulence factors pneumolysin and autolysin. Infect Immun 1999; 67: 2776-82.
33. Bailey AM, Webber MA, Piddock LJ. Medium plays a role in determining expression of acrB, marA, and soxS in Escherichia Coli. Antimicrob Agents Chemother 2006; 50: 1071-4.
34. Munoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 1996; 40: 2252-7.
35. Jones ME, Sahm DF, Martin N et al. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season. Antimicrob Agents Chemother 2000; 44: 462-6.
36. Richter SS, Heilmann KP, Beekmann SE et al. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations. Clin Infect Dis 2005; 40: 225-35.
37. Davies TA, Goldschmidt R, Pfleger S et al. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000). J Antimicrob Chemother 2003; 52: 168-75.
38. Reinert RR, Reinert S, van der LM et al. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 2005; 49: 2903-13.
39. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Sixth Edition: Approved Standard M7-A6. CLSI, Wayne, PA, USA, 2005.
40. Jorgensen JH, Weigel LM, Ferrero MJ et al. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci. Antimicrob Agents Chemother 1999; 43: 329-34.
41. Heaton VJ, Goldsmith CE, Ambler JE et al. Activity of gemifloxacin against penicillin- and ciprofloxacin-resistant Streptococcus pneumoniae displaying topoisomerase- and efflux-mediated resistance mechanisms. Antimicrob Agents Chemother 1999; 43: 2998-3000.
42. Piddock LJ, Johnson MM, Simjee S et al. Expression of efflux: Pump gene pmrA in fluoroquinolone-resistant and -susceptible clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2002; 46: 808-12.
43. Montanari MP, Tili E, Cochetti I et al. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy. Microb Drug Resist 2004; 10: 209-17.
44. Martinez-Garriga B, Vinuesa T, Hernandez-Borrell J et al. The contribution of efflux pumps to quinolone resistance in Streptococcus pneumoniae clinical isolates. Int J Med Microbiol 2007; 297 187-95.
45. Weigel LM, Anderson GJ, Facklam RR et al. Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001; 45: 3517-23.
46. Kays MB, Smith DW, Wack ME et al. Levofloxacin treatment failure in a patient with fluoroquinolone-resistant Streptococcus pneumoniae pneumonia. Pharmacotherapy 2002; 22: 395-9.